Member Info for TrekMadone

Someone’s on the ball, lol! And two insti’s buying in! Lots of reading for the weekend!

No wonder we couldn’t buy earlier!

Trek

Hi shiraz,

There are some good posts on this BB, also rns’s, Company website and proactive investors. Also read cv’s of BoD and understand shareholding’s and rule 9 of takeover code.

I’d have a read through the posts here now before the bb fills up with 5min commentaries on the sp! Lol!

Trek

Thanks isas, I confess to only reading all the ones listed here. I’ll have a dig further back on the website.

Trek

I am amazed at how late folk leave it on AIM.

AISC sub 800! All permits in place. Just the financing which is days away.

Pretty good punt this one, buy sell half, trade, invest, whatever floats. A resource proven tailings project is pretty much a no brainier once it has the environmentals and the finance.

Trek

And this...

“Andromeda JV Stage 1 earn-in

The Company has reached an agreement with its JV partner, Andromeda Metals Ltd, to extend the Stage 1 earn-in timeframe by two months to the 31st December 2020, largely due to the impact of COVID-19 travel restrictions. Whilst the Company was scheduled to meet its $A2.1 Stage 1 earn-in commitment by the due date, both parties felt that an extension of two months would maximise the value of the planned drilling programmes.”

There really isn’t much info about the Andromeda terms. We know they have 25% and I am assuming they are sharing costs by some method or another.

I thought the interviewer asked some good questions. A big positive was the finance being in place, pretty much right through next year. Also nice to see ones research align. So that means 3p will probables be reached and then the 4.5p. The 1m oz is the director trigger or 10m mcap.

Add to that the commitment to providing continuous newsflow and the rarity of the iocg targets and that we have a good read on one. Then even with a longer than anticipated campaign there are still obvious price points. an iocg find would of course be significant and can wait 5 years?

I thought CM was over cautious with the timing of 3-5 years. Of course we get why but he could have shown a bit more urgency around timescales.

Consequently what we have now is a few investors selling as they think they can make a million elsewhere in 6 months. Good luck!

Back to Andromeda, I think if the drills are good the pace will be forced to catch the POG and the only holding factor will be the pace of paperwork.

Atb

Trek

Hi Mcmullank,

Thank you for pointing that out. Hope you are blue soon. I think this will get to 20p given what we know from previous drill results, just a question of when.

Trek

“another excellent hindsight commentator. Amazing how they all seem to appear after the fact. Never before...”

Lol Stewart! You should check my posts in January when I called short on LLOY, TUI, EZJ and HSBA...

Here’s a flavour from 22nd Jan on HSBA bb at 588p

“Well i’m Short to 551, double bottom on its way may let ride or go long to 5.98. Hsba will drop with the impending travel restrictions it will bring out the shorts and sellers. Sars took 6 months to fizzle out. Don’t wish any ill on folk but no difference to hedging poo based on tensions. Only a small position taken. Gla and hope this is contained.”

Then...31st Jan

“Booom! Just check my SB account and 551 gone. Cashed out automatically 40pts. Probably more to go but leave it for the next person. Mmmm now where to buy? May add some BYOT sticking with the theme.

Or 4th Feb

“Sat on my hands atm here, this market is a dead cat. Trump is using the cv to exact insidious squeeze on Chinese economy but refusing entry to US and electioneering off the back of it oh how they love the protectionism! Peeps don’t realise how bad this is. I mean imagine building a 1000 bed hospital in the middle of Hyde park the weekend and telling everybody it’s nothing to worry about and don’t scaremonger. The bug is out. Bought WSG today and ncyt on the dip. Will go short here again and at BP soon just need these false hopes to peak, missed the long though from 551.
GLA whatever your position.”

You can read the posts including my buys at NCYT at 98p from memory. I was wrong there as I should have bought at 48p! Also bought many other covid stocks in Jan/Feb and folk thought I was nuts!

For sure they haven’t all been winners but most have and I did presciently call the covid impact on banking, travel and insurers pretty well. Travel will pick up with testing but banking and insurers have a long way to go. Buying them at or near the bottom of the cycle is generally a good long term play. Question is where is the bottom. I think around 150. Could be a tad higher or a tad less but it defo wasn’t 200p and no there won’t be a 10% yield!

All imo

Atb

Trek

Trek

Trek

Hardly needs any seatbelts!

I sold my last shares at 3.2 with a 1.2 average and traded the spike here very successfully in the preceding years.

This could actually rise when the complete.....

“(vi) Final review of well costings and budget.”

The market is pricing in the good news but it knows there is more to come. I suspect it’s even a condition of the environmentals.

I would rather pay 4p knowing they have financed it appropriately than 3p that could result in more dilution at 2p. Just my take as per my earlier post. All said those at around 2p are sat pretty well from this point as a placing should be at or higher than the recent Bahamian investor buy in.

GLA

Trek

Well here comes my usual contrarian view, that said I have done ok from BPC...

“(vi) Final review of well costings and budget.

BPC will provide further details on the operational readiness of Perseverance #1 well as the project plan advances.”

I expect the review to result in a cash raise. Why, they are on fumes. There is no contingency for a second drill or sidetrack.

You simply cannot afford to move top kit like this hoping that one drill will be enough. Even if they strike they will need cash, obviously the sp will be higher but it’s better to get it done following the euphoria of this RNS and then raise again if they strike. The reason is if they miss the next raise could be at fractions of a penny and the costs become more expensive with a rig sat waiting to be paid. They need contingency and that costs money.

Once they announce a placing that’s the time to top up/buy imo.

All said enjoy the rise today guys.

Atb

Trek

I wouldn’t say pointless as they are confident in the tests to date. But DB has defo put a dampener on it with his closing statement.

I mean why isn’t the saliva kit installed?how did the get confidence if it wasn’t installed and basically why couldn’t they have done both at the same time or even much quicker.

Yep I am sure there are loads of techy reasons but the market will be the judge.

I am holding still but pretty disappointed at the apparent pace of some of these companies. We could even have a vax before some tests are validated. Now that is something I never believed was possible so what do I know.

Trek

‘What smell’

making false claims because they had invested private fortunes in the product. Ramping it without the requisite data.

All they had to say is we have this machine with all this potential and once/if the data has been verified and it has been accredited by the regulators we have a route to market and will update appropriately.

It’s not difficult! Now iAbra have sowed the seeds of distrust. To be fair to TTG saying nothing and the director buys have been the best response. After all they are just supplying the parts and iAbra are their customer.

Trek

The newly announced iAbra Virolens tests - trialled at Heathrow Airport and apparently capable of delivering a result from saliva in 20 seconds - were also not supported by any published evidence, Professor Deeks said, and the company's information pack did not include key data backing up their performance claims.

A spokesman for the test's manufacturer told The Telegraph the team had "significant expertise" and were focused on developing a machine capable of delivering the technology at scale.

"It has the potential to make a significant difference to Covid testing, but it is currently embarking on functional and clinical trials and it wouldn’t be appropriate to comment further until the results of those are known," a spokeman for the test developer added. "We are poised to roll-out once we receive the requisite approval.”

https://www.telegraph.co.uk/global-health/science-and-disease/market-coronavirus-tests-wild-west-says-expert/

Trek

If peeps bought the 20-27p run and are now looking at big losses just after a couple sessions I get their frustration. Thing is though ones research on aim surely points to many bags from the point of investment and you gotta be prepared to sit or average down on a 50% drop. It’s how it works here. Then chuck in the macro risk. Risk of capital raise at lower sp, after all many cos come to aim to raise money so why the surprise when they do.

Sorry I don’t buy the hard luck stories and defo not the acrimony. DYOR and you push the button means what it says, spreading risk, only invest what you can afford to loose etc. I guess we all only sing when we are winning but a few down days don’t justify the behaviours from some on these BB.

To own any shares puts us in like the wealthiest 10% in the whole world and to be born in The West is akin to a lottery win. Most of us already have what we think we are looking for.

Health is wealth!

Trek

Wow over £600k of buys gone through close together! That takes some doing getting those with this stock!

Re other Pharma. Got a few on the watchlist waiting for price entry but my biggest holding is DDDD & SNG in the pure biotech space and ORPH, AVCT & GDR which are more test orientated and small positions in IQAI and SYM.

The first four I have free or nearly free carries having traded them so what’s left can ride now. I did buy ERGO, another quiet stock and sold after it did nothing no matter how good the news was! It them went on to bag after I sold!

I also held SAR, it was a dog and I sold at a loss, twice! It’s not easy. AVCT and SNG could go either way now primarily because of time taken to get products out. Research is key. ONC are unique insofar as the have a niche with high barriers to entry and are driving revs. The risk is with the big Pharma that use their tools. A bit like selling shovels to gold prospectors!

Atb

Trek

Unloved? But PSS loves us!

“Material upside Directa Plus is a commercially proven graphene supplier with a unique production process that creates high quality materials that are already used in a wide array of products internationally across multiple verticals. We expect the company to reach EBITDA positive in FY22 with existing cash reserves, leaving material upside in our expectations from some of its recently developed products such as the Co-Mask and Gipave. We see Directa Plus as an underappreciated, undervalued and more mature and lower risk play in the UK listed graphene and speciality nanomaterials space and initiate with a Buy recommendation and 122p target price. “

Nant Capital LLC (Patrick Soon Shiong) 28.9%
Dompe Sergio 12.3%
Unicorn Asset Management Ltd. 8.7%
Finanziaria Le Perray SpA 6.9%
Giulio Cesareo 6.2%

Trek

Masks proven against Covid-19. Not many companies have been able to get lab access to prove products against a live virus.

“Face masks Directa Plus is based in Lomazzo, Lombardy, Northern Italy, which was one of the first regions in Europe to be hit hard by the coronavirus pandemic. It was therefore also one of the first regions to mandate the wearing of face masks and the Directa Plus management quickly saw the opportunity to use its technology to improve the performance of face masks not just in terms of the thermal performance and comfort, but also enhanced medical properties: antibacterial and anti-viral, the latter of which has now been proven specifically with SARS-CoV2. We believe sales are already averaging over €50k/month, but as the Co-Mask is unique in that it has proven anti-viral performance with COVID-19, designed to be lower cost than alternatives for regular use, and is customisable (logos and images can be printed on the outer fabric), the company should be in a position to secure significant orders from large organisations in due course. These are left as upside in our model but could completely be transformative for the company over the next year. ”

Also it’s upside risk not in 122p buy note. Page 22

Trek

Totally agree.

Trek

“Well despite my Avacta play treading water lately my other pharma play looks to have come good today it would appear. Still hoping Avacta comes out with something soon also....”

Yes there have been several in the covid space including ORPH.

For those looking for something else, a test that can detect cancer using autoantibodies 4 years before it manifests then check out ONC. Their lung cancer trial was the biggest P3 of its kind in the world and it’s just being commercialised. 4 Pharma majors signed up + NHS, US, Germany, UK distribution networks set up and China/Russia coming on next. They have much more as well + cash. 90m mcap.

Usual caveats but I do have several free or near free carries now and ONC has bagged once but got lots of legs.

Atb

Trek

Amazing news for humankind and our investments

“ There is likely to be intense demand for its services and larger facilities may be opened later.”

Supply and demand = top $$

Trek

Well thanks Mr Market I picked up a few! Reminds me of another recent blazing opportunity!

Trek